Literature DB >> 25623049

European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?

M Malvezzi1, P Bertuccio2, T Rosso3, M Rota2, F Levi4, C La Vecchia5, E Negri2.   

Abstract

BACKGROUND: Cancer mortality statistics for 2015 were projected from the most recent available data for the European Union (EU) and its six more populous countries. Prostate cancer was analysed in detail. PATIENTS AND METHODS: Population and death certification data from stomach, colorectum, pancreas, lung, breast, uterus, prostate, leukaemias and total cancers were obtained from the World Health Organisation database and Eurostat. Figures were derived for the EU, France, Germany, Italy, Poland, Spain and the UK. Projected 2015 numbers of deaths by age group were obtained by linear regression on estimated numbers of deaths over the most recent time period identified by a joinpoint regression model.
RESULTS: A total of 1,359,100 cancer deaths are predicted in the EU in 2015 (766,200 men and 592,900 women), corresponding to standardised death rates of 138.4/100,000 men and 83.9/100,000 women, falling 7.5% and 6%, respectively, since 2009. In men, predicted rates for the three major cancers (lung, colorectum and prostate) are lower than in 2009, falling 9%, 5% and 12%. Prostate cancer showed predicted falls of 14%, 17% and 9% in the 35-64, 65-74 and 75+ age groups. In women, breast and colorectal cancers had favourable trends (-10% and -8%), but predicted lung cancer rates rise 9% to 14.24/100,000 becoming the cancer with the highest rate, reaching and possibly overtaking breast cancer rates--though the total number of deaths remain higher for breast (90 800) than lung (87 500). Pancreatic cancer has a negative outlook in both sexes, rising 4% in men and 5% in women between 2009 and 2015.
CONCLUSIONS: Cancer mortality predictions for 2015 confirm the overall favourable cancer mortality trend in the EU, translating to an overall 26% fall in men since its peak in 1988, and 21% in women, and the avoidance of over 325,000 deaths in 2015 compared with the peak rate.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Europe; cancer; mortality; projections; prostate cancer; time trends

Mesh:

Year:  2015        PMID: 25623049     DOI: 10.1093/annonc/mdv001

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  105 in total

1.  Coffee provides a natural multitarget pharmacopeia against the hallmarks of cancer.

Authors:  François Gaascht; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2015-11-17       Impact factor: 5.523

Review 2.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.

Authors:  Marius Ilie; Véronique Hofman; Manfred Dietel; Jean-Charles Soria; Paul Hofman
Journal:  Virchows Arch       Date:  2016-02-25       Impact factor: 4.064

Review 3.  Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review.

Authors:  Mahdi Gharaibeh; J Lyle Bootman; Ali McBride; Jennifer Martin; Ivo Abraham
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

Review 4.  Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

Authors:  Christoforos Kosmidis; Konstantinos Sapalidis; Efstathios Kotidis; Nikolaos Mixalopoulos; Paul Zarogoulidis; Drosos Tsavlis; Sofia Baka; Yan-Gao Man; John Kanellos
Journal:  Ann Transl Med       Date:  2016-05

5.  NEAT1 regulates pancreatic cancer cell growth, invasion and migration though mircroRNA-335-5p/c-met axis.

Authors:  Jia Cao; Yi Zhang; Jiachun Yang; Sijia He; Mingming Li; Shiyan Yan; Ying Chen; Chunying Qu; Leiming Xu
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

6.  Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Authors:  E Alegre; J P Fusco; P Restituto; D Salas-Benito; M E Rodríguez-Ruiz; M P Andueza; M J Pajares; A Patiño-García; R Pio; M D Lozano; A Gúrpide; J M Lopez-Picazo; I Gil-Bazo; J L Perez-Gracia; A Gonzalez
Journal:  Tumour Biol       Date:  2016-07-29

7.  Assessing predicted age-specific breast cancer mortality rates in 27 European countries by 2020.

Authors:  R Clèries; R M Rooney; M Vilardell; J A Espinàs; T Dyba; J M Borras
Journal:  Clin Transl Oncol       Date:  2017-07-19       Impact factor: 3.405

8.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.

Authors:  Claudia Stumpf; Daniel Kaemmerer; Elisa Neubauer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

Review 9.  Pancreatic cancer: Are "liquid biopsies" ready for prime-time?

Authors:  Alexandra R Lewis; Juan W Valle; Mairead G McNamara
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

Review 10.  Current medical treatment of estrogen receptor-positive breast cancer.

Authors:  Franco Lumachi; Davide A Santeufemia; Stefano Mm Basso
Journal:  World J Biol Chem       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.